Cargando…
Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics
BACKGROUND: Alzheimer’s disease (AD) is the leading cause of dementia affecting greater than 26 million people worldwide. Although cerebrospinal fluid (CSF) levels of Aβ(42), tau, and p-tau(181) are well established as diagnostic biomarkers of AD, there is a need for additional CSF biomarkers of neu...
Autores principales: | Wildsmith, Kristin R, Schauer, Stephen P, Smith, Ashley M, Arnott, David, Zhu, Yuda, Haznedar, Joshua, Kaur, Surinder, Mathews, W Rodney, Honigberg, Lee A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061120/ https://www.ncbi.nlm.nih.gov/pubmed/24902845 http://dx.doi.org/10.1186/1750-1326-9-22 |
Ejemplares similares
-
Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays
por: Schauer, Stephen P., et al.
Publicado: (2018) -
Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease
por: Khoonsari, Payam Emami, et al.
Publicado: (2016) -
Alzheimer disease pathology and the cerebrospinal fluid proteome
por: Dayon, Loïc, et al.
Publicado: (2018) -
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)
por: Salloway, Stephen, et al.
Publicado: (2018) -
Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease
por: Bader, Jakob M, et al.
Publicado: (2020)